Technology

Zymeworks

$48.37
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$3.79 (-7.27%) Today
$0.00 (0.00%) As of 12:00 PM UTC after-hours

Why Robinhood?

You can buy or sell Zymeworks and other stocks, options, and ETFs commission-free!

About ZYME

Zymeworks Inc., also called Zymeworks, is a clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of biotherapeutics. Its product, ZW25 and ZW49 are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. The listed name for ZYME is Zymeworks Inc.

CEO
Ali Tehrani
Employees
256
Headquarters
Vancouver, British Columbia
Founded
2003
Market Cap
2.19B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
651.34K
High Today
$51.19
Low Today
$47.37
Open Price
$50.96
Volume
548.95K
52 Week High
$59.03
52 Week Low
$20.33

Collections

ZYME News

Reuters1h

Russian court to hear Kremlin foe Navalny's arrest appeal on Jan 28 - ally

TipRanks The biotech sector has started the year with a bang. The industry benchmark, iShares NASDAQ Biotechnology ETF (IBB), is up ~11% so far in January -- f

ZYME Earnings

-$1.43
-$0.95
-$0.48
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 1, After Hours

You May Also Like

CDAK
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure